Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma.

British journal of cancer - 1 Jul 2023

Angeles Arlou Kristina, Janke Florian, Daum Ann-Kathrin, Reck Martin, Schneider Marc A, Thomas Michael, Christopoulos Petros, Sültmann Holger

Abstract excerpt

BACKGROUND: Detection of circulating tumour DNA (ctDNA) in biological fluids is a minimally invasive alternative to tissue biopsy for therapy monitoring. Cytokines are released in the tumour microenvironment to influence inflammation and tumorigenic mechanisms. Here, we investigated the potential biomarker utility of circulating cytokines vis-à-vis ctDNA in ALK-rearranged+ lung adenocarcinoma (ALK + NSCLC) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytokines

Share to Interleukin-10

Share to Interleukin-6

Share to Interleukin-8

Share to Receptor Protein-Tyrosine Kinases

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37120670
DOI: 10.1038/s41416-023-02284-0
PMCID: PMC10307797

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma.PMID 37120670Read ↗

IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T-Lymphocyte Subpopulations in Patients Treated for Lung AdenocarcinomaSemantic proximity Read ↗

Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner.Semantic proximity Read ↗

Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitorsSemantic proximity Read ↗

Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.Semantic proximity Read ↗

The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Semantic proximity Read ↗

Decoding circulating tumor DNA to identify durable benefit from immunotherapy in lung cancer.Semantic proximity Read ↗

Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.